Skip to main content
Erschienen in: Annals of Surgical Oncology 6/2013

01.06.2013 | Melanomas

How Often do Level III Nodes Bear Melanoma Metastases and does it Affect Patient Outcomes?

verfasst von: Carolyn Nessim, MD, Calvin Law, MD, Yarrow McConnell, MD, Sade Shachar, MD, Gregory McKinnon, MD, Frances Wright, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 6/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

Limited data exist regarding the necessity of resecting level three nodes as part of an axillary dissection for melanoma. The objective of this study was to determine how often level III nodes have metastases, in patients with sentinel lymph node (SLN) positive, palpable and bulky axillary disease, and to determine patient outcomes.

Methods

A retrospective chart review was completed at two tertiary care centers of patients with melanoma that had level three axillary dissections. At the time of surgery, the level III nodes were sent as a separate specimen. Bulky disease was defined as a large mass in all three levels that could not be separated.

Results

A total of 117 patients were identified. Three percent and 18 % of patients with SLN+ and palpable disease, respectively, had further disease in their level III nodes. All bulky patients had level III disease. Those with level III disease had a worse 3-year overall survival than those who did not (15.2 vs. 61.1 %, p < 0.001). For patients with palpable and bulky disease, systemic recurrence rate was 65 and 88 %, with a median time to metastases of 13.6 and 2 months, respectively.

Conclusions

Patients with SLN+ disease rarely have positive level III nodes, questioning the need for routine removal of these nodes. Patients with palpable and bulky lymph node disease have implied occult distant metastases at the time of diagnosis and treatment. With the advent of improved targeted therapies for melanoma, clinical trials evaluating their role in patients with stage III disease may be warranted to improve patient outcomes.
Literatur
1.
Zurück zum Zitat Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American joint committee on cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19:3622–34.PubMed Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American joint committee on cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19:3622–34.PubMed
2.
Zurück zum Zitat Bevilacqua RG, Coit DG, Rogatko A, Younes RN, Brennan MF. Axillary dissection in melanoma: prognostic variables in node-positive patients. Ann Surg. 1990; 212:125–31.PubMedCrossRef Bevilacqua RG, Coit DG, Rogatko A, Younes RN, Brennan MF. Axillary dissection in melanoma: prognostic variables in node-positive patients. Ann Surg. 1990; 212:125–31.PubMedCrossRef
3.
Zurück zum Zitat Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355:1307–17.PubMedCrossRef Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355:1307–17.PubMedCrossRef
4.
Zurück zum Zitat Wright F, Spithoff K, Easson A, Murray C, Toye J, McCready D, Patrella T. Primary excision margins and sentinel lymph node biopsy in clinically node-negative melanoma of the trunk and extremities. Clin Oncol. 2011;23:572–8.CrossRef Wright F, Spithoff K, Easson A, Murray C, Toye J, McCready D, Patrella T. Primary excision margins and sentinel lymph node biopsy in clinically node-negative melanoma of the trunk and extremities. Clin Oncol. 2011;23:572–8.CrossRef
5.
Zurück zum Zitat Plitas G, Aryian CE. Controversies in the management of regional nodes in melanoma. J NCCN. 2012;10:414–21. Plitas G, Aryian CE. Controversies in the management of regional nodes in melanoma. J NCCN. 2012;10:414–21.
6.
Zurück zum Zitat Mack LA, McKinnon G. Controversies in the management of metastatic melanoma to regional lymphatic basins. J Surg Oncol. 2004;86:189–99.PubMedCrossRef Mack LA, McKinnon G. Controversies in the management of metastatic melanoma to regional lymphatic basins. J Surg Oncol. 2004;86:189–99.PubMedCrossRef
7.
Zurück zum Zitat Ariyan C, Brady MS, Gönen M, Busam K, Coit D. Positive non-sentinel node status predicts mortality in patients with cutaneous melanoma. Ann Surg Oncol. 2009;16:186–90.PubMedCrossRef Ariyan C, Brady MS, Gönen M, Busam K, Coit D. Positive non-sentinel node status predicts mortality in patients with cutaneous melanoma. Ann Surg Oncol. 2009;16:186–90.PubMedCrossRef
8.
Zurück zum Zitat Ghaferi AA, Wong SL, Johnson TM, et al. Prognostic significance of a positive nonsentinel lymph node in cutaneous melanoma. Ann Surg Oncol. 2009;16:2978–84.PubMedCrossRef Ghaferi AA, Wong SL, Johnson TM, et al. Prognostic significance of a positive nonsentinel lymph node in cutaneous melanoma. Ann Surg Oncol. 2009;16:2978–84.PubMedCrossRef
9.
Zurück zum Zitat Easson AM, Rotstein LE, McCready DR. Lymph node assessment in melanoma. J Surg Oncol. 2009;99:176–85.PubMedCrossRef Easson AM, Rotstein LE, McCready DR. Lymph node assessment in melanoma. J Surg Oncol. 2009;99:176–85.PubMedCrossRef
10.
Zurück zum Zitat Karakousis CP. Therapeutic Node Dissections in Malignant Melanoma. Ann Surg Oncol. 1998;5:473–82.PubMedCrossRef Karakousis CP. Therapeutic Node Dissections in Malignant Melanoma. Ann Surg Oncol. 1998;5:473–82.PubMedCrossRef
11.
Zurück zum Zitat Meyer T, Merkel S, Göhl J, Hohenberger W. Lymph node dissection for clinically evident lymph node metastases of malignant melanoma. EJSO. 2002; 28:424–30.PubMedCrossRef Meyer T, Merkel S, Göhl J, Hohenberger W. Lymph node dissection for clinically evident lymph node metastases of malignant melanoma. EJSO. 2002; 28:424–30.PubMedCrossRef
12.
Zurück zum Zitat van Akkooi ACJ, Bouwhuis MG, van Geel AN, et al. Morbidity and prognosis after therapeutic lymph node dissections for malignant melanoma. EJSO. 2007;33:102–8.PubMedCrossRef van Akkooi ACJ, Bouwhuis MG, van Geel AN, et al. Morbidity and prognosis after therapeutic lymph node dissections for malignant melanoma. EJSO. 2007;33:102–8.PubMedCrossRef
13.
Zurück zum Zitat Young SE, Martinez SR, Faries MB, Essner R, Wanek LA, Morton DL. Can surgical therapy alone achieve long-term cure of melanoma metastatic to regional nodes? Cancer J. 2006;12:207–11.PubMedCrossRef Young SE, Martinez SR, Faries MB, Essner R, Wanek LA, Morton DL. Can surgical therapy alone achieve long-term cure of melanoma metastatic to regional nodes? Cancer J. 2006;12:207–11.PubMedCrossRef
14.
Zurück zum Zitat Wrightson WR, Wong SL, Edwards MJ, et al. Complications associated with sentinel lymph node biopsy for melanoma. Ann Surg. 2003;10:676–80.CrossRef Wrightson WR, Wong SL, Edwards MJ, et al. Complications associated with sentinel lymph node biopsy for melanoma. Ann Surg. 2003;10:676–80.CrossRef
15.
Zurück zum Zitat Tominaga T, Takashima S, Danno M. Randomized clinical trial comparing level II and level III node dissection in addition to mastectomy for breast cancer. Br J Surg. 2004;91:38–43.PubMedCrossRef Tominaga T, Takashima S, Danno M. Randomized clinical trial comparing level II and level III node dissection in addition to mastectomy for breast cancer. Br J Surg. 2004;91:38–43.PubMedCrossRef
16.
Zurück zum Zitat Larson D, Weinstein M, Goldberg I et al. Edema of the arm as a function of the extent of axillary surgery in patients with stage I–II carcinoma of the breast treated with primary radiotherapy. Int J Radiat Oncol Biol Phys. 1986;12:1575–82.PubMedCrossRef Larson D, Weinstein M, Goldberg I et al. Edema of the arm as a function of the extent of axillary surgery in patients with stage I–II carcinoma of the breast treated with primary radiotherapy. Int J Radiat Oncol Biol Phys. 1986;12:1575–82.PubMedCrossRef
17.
Zurück zum Zitat Pezner RD, Patterson MR, Hill LR et al. Arm Lymphedema in patients treated conservatively for breast cancer: relationship to patient age and axillary node dissection technique. Int J Radiat Oncol Biol Phys. 1986;12:2079–83.PubMedCrossRef Pezner RD, Patterson MR, Hill LR et al. Arm Lymphedema in patients treated conservatively for breast cancer: relationship to patient age and axillary node dissection technique. Int J Radiat Oncol Biol Phys. 1986;12:2079–83.PubMedCrossRef
18.
20.
Zurück zum Zitat Namm JP, Chang AE, Cimmino VM, Rees RS, Johnson TM, Sabel MS. Is a level III dissection necessary for a positive sentinel lymph node in melanoma? J Surg Oncol. 2012;105:225–8.PubMedCrossRef Namm JP, Chang AE, Cimmino VM, Rees RS, Johnson TM, Sabel MS. Is a level III dissection necessary for a positive sentinel lymph node in melanoma? J Surg Oncol. 2012;105:225–8.PubMedCrossRef
21.
Zurück zum Zitat Bilimoria KY, Raval MV, Bentrem DJ, Wayne JD, Balch CM, Ko CY. National assessment of melanoma care using formally developed quality indicators. J Clin Oncol. 2009;27:544–57. Bilimoria KY, Raval MV, Bentrem DJ, Wayne JD, Balch CM, Ko CY. National assessment of melanoma care using formally developed quality indicators. J Clin Oncol. 2009;27:544–57.
22.
Zurück zum Zitat Saha S, Farrar WB, Young DC, Ferrara JJ, Burak WE. Variation in axillary node dissection influences the degree of nodal involvement in breast cancer patients. J Surg Oncol. 2000;73:134–7.PubMedCrossRef Saha S, Farrar WB, Young DC, Ferrara JJ, Burak WE. Variation in axillary node dissection influences the degree of nodal involvement in breast cancer patients. J Surg Oncol. 2000;73:134–7.PubMedCrossRef
23.
Zurück zum Zitat Valsecchi ME, Silbermins D, deRosa N, Wong SL, Lyman GH. Lymphatic mapping and sentinel lymph node biopsy in patients with melanoma: a meta-analysis. J Clin Oncol. 2011;29:1479–87.PubMedCrossRef Valsecchi ME, Silbermins D, deRosa N, Wong SL, Lyman GH. Lymphatic mapping and sentinel lymph node biopsy in patients with melanoma: a meta-analysis. J Clin Oncol. 2011;29:1479–87.PubMedCrossRef
24.
Zurück zum Zitat Ross MI, Gershenwald JE. Evidence-based treatment of early-stage melanoma. J Surg Oncol. 2011;104:341–53.PubMed Ross MI, Gershenwald JE. Evidence-based treatment of early-stage melanoma. J Surg Oncol. 2011;104:341–53.PubMed
25.
Zurück zum Zitat Cadili A, McKinnon G, Wright F, Hanna W, Macintosh E, Abhari Z, Dabbs K. Validation of a scoring system to predict non-sentinel lymph node metastasis in melanoma. J Surg Oncol. 2010;101:191–4.PubMed Cadili A, McKinnon G, Wright F, Hanna W, Macintosh E, Abhari Z, Dabbs K. Validation of a scoring system to predict non-sentinel lymph node metastasis in melanoma. J Surg Oncol. 2010;101:191–4.PubMed
26.
Zurück zum Zitat Balch CM, Gershenwald JE, Soong S-J, et al. Multivariate analysis of prognostic factors among 2313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol. 2010;28:2452–59.PubMedCrossRef Balch CM, Gershenwald JE, Soong S-J, et al. Multivariate analysis of prognostic factors among 2313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol. 2010;28:2452–59.PubMedCrossRef
27.
Zurück zum Zitat Calabro A, Singletary SE, Balch CM. Patterns of relapse in 1001 consecutive patients with melanoma nodal metastases. Arch Surg. 1989;124:1051–55.PubMedCrossRef Calabro A, Singletary SE, Balch CM. Patterns of relapse in 1001 consecutive patients with melanoma nodal metastases. Arch Surg. 1989;124:1051–55.PubMedCrossRef
28.
Zurück zum Zitat Balch CM, Soong SJ, Murad TM, et al. A multifactorial analysis of melanoma: III. Prognostic factors in melanoma patients with lymph node metastases (stage II). Ann Surg. 1981;193:377–88.PubMedCrossRef Balch CM, Soong SJ, Murad TM, et al. A multifactorial analysis of melanoma: III. Prognostic factors in melanoma patients with lymph node metastases (stage II). Ann Surg. 1981;193:377–88.PubMedCrossRef
30.
Zurück zum Zitat Lee B, Mukhi N, Liu D. Current management and novel agents for malignant melanoma. J Hematol Oncol. 2012;5:3-7.PubMedCrossRef Lee B, Mukhi N, Liu D. Current management and novel agents for malignant melanoma. J Hematol Oncol. 2012;5:3-7.PubMedCrossRef
31.
Zurück zum Zitat Scolyer RA, Long GV, Thompson JF. Evolving concepts in melanoma classification and their relevance to multidisciplinary melanoma patient care. Molecular Oncol. 2011;5:124–36.CrossRef Scolyer RA, Long GV, Thompson JF. Evolving concepts in melanoma classification and their relevance to multidisciplinary melanoma patient care. Molecular Oncol. 2011;5:124–36.CrossRef
32.
Zurück zum Zitat Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507–16.PubMedCrossRef Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507–16.PubMedCrossRef
33.
Zurück zum Zitat Gajewski TF. Molecular Profiling of melanoma and the evolution of patient-specific therapy. Sem Oncol. 2011;38:236–42.CrossRef Gajewski TF. Molecular Profiling of melanoma and the evolution of patient-specific therapy. Sem Oncol. 2011;38:236–42.CrossRef
34.
Zurück zum Zitat Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711.PubMedCrossRef Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711.PubMedCrossRef
35.
Zurück zum Zitat Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517.PubMedCrossRef Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517.PubMedCrossRef
Metadaten
Titel
How Often do Level III Nodes Bear Melanoma Metastases and does it Affect Patient Outcomes?
verfasst von
Carolyn Nessim, MD
Calvin Law, MD
Yarrow McConnell, MD
Sade Shachar, MD
Gregory McKinnon, MD
Frances Wright, MD
Publikationsdatum
01.06.2013
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 6/2013
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-013-2880-2

Weitere Artikel der Ausgabe 6/2013

Annals of Surgical Oncology 6/2013 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.